

# Detailed Contents

<b>Chapter 1</b>		<b>Chapter 2</b>	
<b>Elements of the Immune System and their Roles in Defense</b>		<b>Innate Immunity: the Immediate Response to Infection</b>	
	<b>1</b>		<b>29</b>
1-1	Numerous commensal microorganisms inhabit healthy human bodies	2-1	Physical barriers colonized by commensal microorganisms protect against infection by pathogens
	2		29
1-2	Pathogens are infectious organisms that cause disease	2-2	Intracellular and extracellular pathogens require different types of immune response
	3		30
1-3	The skin and mucosal surfaces form barriers against infection	2-3	Complement is a system of plasma proteins that mark pathogens for destruction
	4		31
1-4	The innate immune response causes inflammation at sites of infection	2-4	At the start of an infection, complement activation proceeds by the alternative pathway
	8		32
1-5	The adaptive immune response adds to an ongoing innate immune response	2-5	Regulatory proteins determine the extent and site of C3b deposition
	10		34
1-6	Adaptive immunity is better understood than innate immunity	2-6	Phagocytosis by macrophages provides a first line of cellular defense against invading microorganisms
	12		36
1-7	Immune system cells with different functions all derive from hematopoietic stem cells	2-7	The terminal complement proteins lyse pathogens by forming membrane pores
	12		37
1-8	Immunoglobulins and T-cell receptors are the diverse lymphocyte receptors of adaptive immunity	2-8	Small peptides released during complement activation induce local inflammation
	16		39
1-9	On encountering their specific antigen, B cells and T cells differentiate into effector cells	2-9	Several classes of plasma protein limit the spread of infection
	17		39
1-10	Antibodies bind to pathogens and cause their inactivation or destruction	2-10	Antimicrobial peptides kill pathogens by perturbing their membranes
	18		41
1-11	Most lymphocytes are present in specialized lymphoid tissues	2-11	Pentraxins are plasma proteins of innate immunity that bind microorganisms and target them to phagocytes
	19		43
1-12	Adaptive immunity is initiated in secondary lymphoid tissues		
	20		
1-13	The spleen provides adaptive immunity to blood infections		
	23		
1-14	Most secondary lymphoid tissue is associated with the gut		
	25		
Summary to Chapter 1	26	Summary to Chapter 2	43
Questions	27	Questions	44

## Chapter 3

**Innate Immunity: the Induced Response to Infection**

3-1	Cellular receptors of innate immunity distinguish 'non-self' from 'self'	47
3-2	Tissue macrophages carry a battery of phagocytic and signaling receptors	49
3-3	Recognition of LPS by TLR4 induces changes in macrophage gene expression	51
3-4	Activation of resident macrophages induces a state of inflammation at sites of infection	53
3-5	NOD-like receptors recognize bacterial degradation products in the cytoplasm	54
3-6	Inflammasomes amplify the innate immune response by increasing the production of IL-1 $\beta$	55
3-7	Neutrophils are dedicated phagocytes and the first effector cells recruited to sites of infection	56
3-8	Inflammatory cytokines recruit neutrophils from the blood to the infected tissue	57
3-9	Neutrophils are potent killers of pathogens and are themselves programmed to die	59
3-10	Inflammatory cytokines raise body temperature and activate the liver to make the acute-phase response	62
3-11	The lectin pathway of complement activation is initiated by the mannose-binding lectin	63
3-12	C-reactive protein triggers the classical pathway of complement activation	66
3-13	Toll-like receptors sense the presence of the four main groups of pathogenic microorganisms	66
3-14	Genetic variation in Toll-like receptors is associated with resistance and susceptibility to disease	67
3-15	Internal detection of viral infection induces cells to make an interferon response	68
3-16	Plasmacytoid dendritic cells are factories for making large quantities of type I interferons	71
3-17	Natural killer cells are the main circulating lymphocytes that contribute to the innate immune response	71
3-18	Two subpopulations of NK cells are differentially distributed in blood and tissues	72
3-19	NK-cell cytotoxicity is activated at sites of virus infection	73
3-20	NK cells and macrophages activate each other at sites of infection	75

3-21	Interactions between dendritic cells and NK cells influence the immune response	76
	Summary to Chapter 3	78
	Questions	78

## Chapter 4

	<b>Antibody Structure and the Generation of B-Cell Diversity</b>	<b>81</b>
	The structural basis of antibody diversity	82
4-1	Antibodies are composed of polypeptides with variable and constant regions	82
4-2	Immunoglobulin chains are folded into compact and stable protein domains	83
4-3	An antigen-binding site is formed from the hypervariable regions of a heavy-chain V domain and a light-chain V domain	85
4-4	Antigen-binding sites vary in shape and physical properties	86
4-5	Monoclonal antibodies are produced from a clone of antibody-producing cells	88
4-6	Monoclonal antibodies are used as treatments for a variety of diseases	90
	Summary	91
	Generation of immunoglobulin diversity in B cells before encounter with antigen	91
4-8	Random recombination of gene segments produces diversity in the antigen-binding sites of immunoglobulins	92
4-9	Recombination enzymes produce additional diversity in the antigen-binding site	95
4-10	Developing and naive B cells use alternative mRNA splicing to make both IgM and IgD	96
4-11	Each B cell produces immunoglobulin of a single antigen specificity	96
4-12	Immunoglobulin is first made in a membrane-bound form that is present on the B-cell surface	97
	Summary	98
	Diversification of antibodies after B cells encounter antigen	98
4-13	Secreted antibodies are produced by an alternative pattern of heavy-chain RNA processing	98
4-14	Rearranged V-region sequences are further diversified by somatic hypermutation	100
4-15	Isotype switching produces immunoglobulins with different C regions but identical antigen specificities	101
4-16	Antibodies with different C regions have different effector functions	103

4-17	The four subclasses of IgG have different and complementary functions	105	The major histocompatibility complex	135	
	Summary	107	5-18	The diversity of MHC molecules in the human population is due to multigene families and genetic polymorphism	135
	Summary to Chapter 4	107	5-19	The HLA class I and class II genes occupy different regions of the HLA complex	137
	Questions	110	5-20	Other proteins involved in antigen processing and presentation are encoded in the HLA class II region	138
<b>Chapter 5</b>			5-21	MHC polymorphism affects the binding of peptide antigens and their presentation to T cells	138
	<b>Antigen Recognition by T Lymphocytes</b>	<b>113</b>	5-22	MHC diversity results from selection by infectious disease	140
	T-cell receptor diversity	114	5-23	MHC polymorphism triggers T-cell reactions that can reject transplanted organs	143
5-1	The T-cell receptor resembles a membrane-associated Fab fragment of immunoglobulin	114		Summary	144
5-2	T-cell receptor diversity is generated by gene rearrangement	115		Summary to Chapter 5	144
5-3	The RAG genes were key elements in the origin of adaptive immunity	117		Questions	145
5-4	Expression of the T-cell receptor on the cell surface requires association with additional proteins	117	<b>Chapter 6</b>		
5-5	A distinct population of T cells expresses a second class of T-cell receptor with $\gamma$ and $\delta$ chains	118		<b>The Development of B Lymphocytes</b>	<b>149</b>
	Summary	119		The development of B cells in the bone marrow	150
	Antigen processing and presentation	120	6-1	B-cell development in the bone marrow proceeds through several stages	150
5-6	T-cell receptors recognize peptide antigens bound to MHC molecules	121	6-2	B-cell development is stimulated by bone marrow stromal cells	151
5-7	Two classes of MHC molecule present peptide antigens to two types of T cell	122	6-3	Pro-B-cell rearrangement of the heavy-chain locus is an inefficient process	152
5-8	The two classes of MHC molecule have similar three-dimensional structures	123	6-4	The pre-B-cell receptor monitors the quality of immunoglobulin heavy chains	153
5-9	MHC molecules bind a variety of peptides	124	6-5	The pre-B-cell receptor causes allelic exclusion at the immunoglobulin heavy-chain locus	154
5-10	MHC class I and MHC class II molecules function in different intracellular compartments	125	6-6	Rearrangement of the light-chain loci by pre-B cells is relatively efficient	155
5-11	Peptides generated in the cytosol are transported to the endoplasmic reticulum for binding to MHC class I molecules	126	6-7	Developing B cells pass two checkpoints in the bone marrow	157
5-12	MHC class I molecules bind peptides as part of a peptide-loading complex	127	6-8	A program of protein expression underlies the stages of B-cell development	157
5-13	Peptides presented by MHC class II molecules are generated in acidified intracellular vesicles	129	6-9	Many B-cell tumors carry chromosomal translocations that join immunoglobulin genes to genes that regulate cell growth	160
5-14	Invariant chain prevents MHC class II molecules from binding peptides in the endoplasmic reticulum	130	6-10	B cells expressing the glycoprotein CD5 express a distinctive repertoire of receptors	161
5-15	Cross-presentation enables extracellular antigens to be presented by MHC class I	131		Summary	162
5-16	MHC class I molecules are expressed by most cell types, MHC class II molecules are expressed by few cell types	132		Selection and further development of the B-cell repertoire	163
5-17	The T-cell receptor specifically recognizes both peptide and MHC molecule	132	6-11	The population of immature B cells is purged of cells bearing self-reactive B-cell receptors	164
	Summary	133			

6-12	The antigen receptors of autoreactive immature B cells can be modified by receptor editing	165	7-14	T cells undergo further differentiation in secondary lymphoid tissues after encounter with antigen	193
6-13	Immature B cells specific for monovalent self antigens are made nonresponsive to antigen	166		Summary	194
6-14	Maturation and survival of B cells requires access to lymphoid follicles	167		Summary to Chapter 7	194
6-15	Encounter with antigen leads to the differentiation of activated B cells into plasma cells and memory B cells	168		Questions	196
6-16	Different types of B-cell tumor reflect B cells at different stages of development	170		<b>Chapter 8</b>	
	Summary	170		<b>T Cell-Mediated Immunity</b>	<b>199</b>
	Summary to Chapter 6	172		Activation of naive T cells by antigen	199
	Questions	173	8-1	Dendritic cells carry antigens from sites of infection to secondary lymphoid tissues	200
	<b>Chapter 7</b>		8-2	Dendritic cells are adept and versatile at processing pathogen antigens	202
	<b>The Development of T Lymphocytes</b>	<b>177</b>	8-3	Naive T cells first encounter antigen presented by dendritic cells in secondary lymphoid tissues	203
7-1	T cells develop in the thymus	178	8-4	Homing of naive T cells to secondary lymphoid tissues is determined by chemokines and cell-adhesion molecules	204
7-2	Thymocytes commit to the T-cell lineage before rearranging their T-cell receptor genes	180	8-5	Activation of naive T cells requires signals from the antigen receptor and a co-stimulatory receptor	206
7-3	The two lineages of T cells arise from a common thymocyte progenitor	181	8-6	Signals from T-cell receptors, co-receptors, and co-stimulatory receptors activate naive T cells	207
7-4	Gene rearrangement in double-negative thymocytes leads to assembly of either a $\gamma:\delta$ receptor or a pre-T-cell receptor	183	8-7	Proliferation and differentiation of activated naive T cells are driven by the cytokine interleukin-2	209
7-5	Thymocytes can make four attempts to rearrange a $\beta$ -chain gene	184	8-8	Antigen recognition in the absence of co-stimulation leads to a state of T-cell anergy	210
7-6	Rearrangement of the $\alpha$ -chain gene occurs only in pre-T cells	185	8-9	Activation of naive CD4 T cells gives rise to effector CD4 T cells with distinctive helper functions	211
7-7	Stages in T-cell development are marked by changes in gene expression	186	8-10	The cytokine environment determines which differentiation pathway a naive T cell takes	213
	Summary	188	8-11	Positive feedback in the cytokine environment can polarize the effector CD4 T-cell response	214
	Positive and negative selection of the T-cell repertoire	188	8-12	Naive CD8 T cells require stronger activation than naive CD4 T cells	215
7-8	T cells that recognize self-MHC molecules are positively selected in the thymus	189		Summary	217
7-9	Continuing $\alpha$ -chain gene rearrangement increases the chance for positive selection	190		The properties and functions of effector T cells	218
7-10	Positive selection determines expression of either the CD4 or the CD8 co-receptor	191	8-13	Cytotoxic CD8 T cells and effector CD4 $T_H1$ , $T_H2$ , and $T_H17$ work at sites of infection	218
7-11	T cells specific for self antigens are removed in the thymus by negative selection	192	8-14	Effector T-cell functions are mediated by cytokines and cytotoxins	220
7-12	Tissue-specific proteins are expressed in the thymus and participate in negative selection	192	8-15	Cytokines change the patterns of gene expression in the cells targeted by effector T cells	221
7-13	Regulatory CD4 T cells comprise a distinct lineage of CD4 T cells	193			

8-16	Cytotoxic CD8 T cells are selective and serial killers of target cells at sites of infection	222	9-12	Dimeric IgA protects the mucosal surfaces of the body	246
8-17	Cytotoxic T cells kill their target cells by inducing apoptosis	223	9-13	IgE provides a mechanism for the rapid ejection of parasites and other pathogens from the body	247
8-18	Effector T <sub>H</sub> 1 CD4 cells induce macrophage activation	224	9-14	Mothers provide protective antibodies to their young, both before and after birth	250
8-19	T <sub>FH</sub> cells, and the naive B cells that they help, recognize different epitopes of the same antigen	225	9-15	High-affinity neutralizing antibodies prevent viruses and bacteria from infecting cells	251
8-20	Regulatory CD4 T cells limit the activities of effector CD4 and CD8 T cells	226	9-16	High-affinity IgG and IgA antibodies are used to neutralize microbial toxins and animal venoms	253
	Summary	227	9-17	Binding of IgM to antigen on a pathogen's surface activates complement by the classical pathway	255
	Summary to Chapter 8	227	9-18	Two forms of C4 tend to be fixed at different sites on pathogen surfaces	256
	Questions	228	9-19	Complement activation by IgG requires the participation of two or more IgG molecules	257
	<b>Chapter 9</b>		9-20	Erythrocytes facilitate the removal of immune complexes from the circulation	258
	<b>Immunity Mediated by B Cells and Antibodies</b>	<b>231</b>	9-21	Fc $\gamma$ receptors enable effector cells to bind and be activated by IgG bound to pathogens	258
	Antibody production by B lymphocytes	231	9-22	A variety of low-affinity Fc receptors are IgG-specific	260
9-1	B-cell activation requires cross-linking of surface immunoglobulin	232	9-23	An Fc receptor acts as an antigen receptor for NK cells	261
9-2	B-cell activation requires signals from the B-cell co-receptor	232	9-24	The Fc receptor for monomeric IgA belongs to a different family than the Fc receptors for IgG and IgE	262
9-3	Effective B cell-mediated immunity depends on help from CD4 T cells	234		Summary	263
9-4	Follicular dendritic cells in the B-cell area store and display intact antigens to B cells	235		Summary to Chapter 9	263
9-5	Antigen-activated B cells move close to the T-cell area to find a helper T <sub>FH</sub> cell	236		Questions	264
9-6	The primary focus of clonal expansion in the medullary cords produces plasma cells secreting IgM	238		<b>Chapter 10</b>	
9-7	Activated B cells undergo somatic hypermutation and isotype switching in the specialized microenvironment of the primary follicle	239		<b>Preventing Infection at Mucosal Surfaces</b>	<b>267</b>
9-8	Antigen-mediated selection of centrocytes drives affinity maturation of the B-cell response in the germinal center	241	10-1	The communication functions of mucosal surfaces render them vulnerable to infection	267
9-9	The cytokines made by helper T cells determine how B cells switch their immunoglobulin isotype	243	10-2	Mucins are gigantic glycoproteins that endow the mucus with the properties to protect epithelial surfaces	269
9-10	Cytokines made by helper T cells determine the differentiation of antigen-activated B cells into plasma cells or memory cells	244	10-3	Commensal microorganisms assist the gut in digesting food and maintaining health	269
	Summary	245	10-4	The gastrointestinal tract is invested with distinctive secondary lymphoid tissues	272
	Antibody effector functions	245	10-5	Inflammation of mucosal tissues is associated with causation not cure of disease	273
9-11	IgM, IgG, and monomeric IgA protect the internal tissues of the body	246			

10-6	Intestinal epithelial cells contribute to innate immune responses in the gut	275	11-7	In the secondary immune response, memory B cells are activated whereas naive B cells are inhibited	300
10-7	Intestinal macrophages eliminate pathogens without creating a state of inflammation	276	11-8	Activation of the primary and secondary immune responses have common features	301
10-8	M cells constantly transport microbes and antigens from the gut lumen to gut-associated lymphoid tissue	277	11-9	Combinations of cell-surface markers distinguish memory T cells from naive and effector T cells	302
10-9	Gut dendritic cells respond differently to food, commensal microorganisms, and pathogens	278	11-10	Central and effector memory T cells recognize pathogens in different tissues of the body	304
10-10	Activation of B cells and T cells in one mucosal tissue commits them to defending all mucosal tissues	279	11-11	In viral infections, numerous effector CD8 T cells give rise to relatively few memory T cells	305
10-11	A variety of effector lymphocytes guard healthy mucosal tissue in the absence of infection	281	11-12	Immune-complex-mediated inhibition of naive B cells is used to prevent hemolytic anemia of the newborn	305
10-12	B cells activated in mucosal tissues give rise to plasma cells secreting IgM and IgA at mucosal surfaces	282	11-13	In the response to influenza virus, immunological memory is gradually eroded	306
10-13	Secretory IgM and IgA protect mucosal surfaces from microbial invasion	283		Summary	307
10-14	Two subclasses of IgA have complementary properties for controlling microbial populations	285		Vaccination to prevent infectious disease	308
10-15	People lacking IgA are able to survive, reproduce, and generally remain healthy	286	11-14	Protection against smallpox is achieved by immunization with the less dangerous cowpox virus	308
10-16	T <sub>H</sub> 2-mediated immunity protects against helminth infections	288	11-15	Smallpox is the only infectious disease of humans that has been eradicated worldwide by vaccination	309
Summary to Chapter 10		290	11-16	Most viral vaccines are made from killed or inactivated viruses	310
Questions		292	11-17	Both inactivated and live-attenuated vaccines protect against poliovirus	311
Chapter 11			11-18	Vaccination can inadvertently cause disease	312
<b>Immunological Memory and Vaccination</b>	<b>295</b>		11-19	Subunit vaccines are made from the most antigenic components of a pathogen	313
Immunological memory and the secondary immune response		296	11-20	Invention of rotavirus vaccines took at least 30 years of research and development	313
11-1	Antibodies made in a primary immune response persist for several months and provide protection	296	11-21	Bacterial vaccines are made from whole bacteria, secreted toxins, or capsular polysaccharides	314
11-2	Low levels of pathogen-specific antibodies are maintained by long-lived plasma cells	297	11-22	Conjugate vaccines enable high-affinity antibodies to be made against carbohydrate antigens	315
11-3	Long-lived clones of memory B cells and T cells are produced in the primary immune response	297	11-23	Adjuvants are added to vaccines to activate and enhance the response to antigen	316
11-4	Memory B cells and T cells provide protection against pathogens for decades and even for life	299	11-24	Genome sequences of human pathogens have opened up new avenues for making vaccines	316
11-5	Maintaining populations of memory cells does not depend upon the persistence of antigen	299	11-25	The ever-changing influenza virus requires a new vaccine every year	318
11-6	Changes to the antigen receptor distinguish naive, effector, and memory B cells	300			

11-26	The need for a vaccine and the demands placed upon it change with the prevalence of disease	319	12-14	$V_{\gamma}V_{\gamma}1$ T-cell receptors recognize lipid antigens presented by CD1d	352
11-27	Vaccines have yet to be made against pathogens that establish chronic infections	322		Summary	354
11-28	Vaccine development faces greater public scrutiny than drug development	323		Restriction of $\alpha:\beta$ T cells by non-polymorphic MHC class I-like molecules	354
	Summary	324	12-15	CD1-restricted $\alpha:\beta$ T cells recognize lipid antigens of mycobacterial pathogens	354
Summary to Chapter 11		325	12-16	NKT cells are innate lymphocytes that detect lipid antigens by using $\alpha:\beta$ T-cell receptors	356
Questions		326	12-17	Mucosa-associated invariant T cells detect bacteria and fungi that make riboflavin	357
<b>Chapter 12</b>				Summary	359
<b>Coevolution of Innate and Adaptive Immunity</b>		<b>329</b>		Summary to Chapter 12	360
Regulation of NK-cell function by MHC class I and related molecules		330		Questions	361
12-1	NK cells express a range of activating and inhibitory receptors	330	<b>Chapter 13</b>		
12-2	The strongest receptor that activates NK cells is an Fc receptor	332	<b>Failures of the Body's Defenses</b>	<b>365</b>	
12-3	Many NK-cell receptors recognize MHC class I and related molecules	333	Evasion and subversion of the immune system by pathogens	365	
12-4	Immunoglobulin-like NK-cell receptors recognize polymorphic epitopes of HLA-A, HLA-B, and HLA-C	335	13-1	Genetic variation within some species of pathogens prevents effective long-term immunity	366
12-5	NK cells are educated to detect pathological change in MHC class I expression	336	13-2	Mutation and recombination allow influenza virus to escape from immunity	366
12-6	Different genomic complexes encode lectin-like and immunoglobulin-like NK-cell receptors	339	13-3	Trypanosomes use gene conversion to change their surface antigens	368
12-7	Human KIR haplotypes uniquely come in two distinctive forms	340	13-4	Herpesviruses persist in human hosts by hiding from the immune response	369
12-8	Cytomegalovirus infection induces proliferation of NK cells expressing the activating HLA-E receptor	341	13-5	Some pathogens sabotage or subvert immune defense mechanisms	371
12-9	Interactions of uterine NK cells with fetal MHC class I molecules affect reproductive success	342	13-6	Bacterial superantigens stimulate a massive but ineffective CD4 T-cell response	373
	Summary	345	13-7	Subversion of IgA action by bacterial IgA-binding proteins	374
Maintenance of tissue integrity by $\gamma:\delta$ T cells		347		Summary	375
12-10	$\gamma:\delta$ T cells are not governed by the same rules as $\alpha:\beta$ T cells	347	Inherited immunodeficiency diseases	375	
12-11	$\gamma:\delta$ T cells in blood and tissues express different $\gamma:\delta$ receptors	348	13-8	Rare primary immunodeficiency diseases reveal how the human immune system works	375
12-12	$V_{\gamma}9:V_{\gamma}2$ T cells recognize phosphoantigens presented on cell surfaces	350	13-9	Inherited immunodeficiency diseases are caused by dominant, recessive, or X-linked gene defects	377
12-13	$V_{\gamma}4:V_{\gamma}5$ T cells detect both virus-infected cells and tumor cells	351	13-10	Recessive and dominant mutations in the IFN- $\gamma$ receptor cause diseases of differing severity	378
			13-11	Antibody deficiency leads to poor clearing of extracellular bacteria	379

13-12	Diminished production of antibodies also results from inherited defects in T-cell help	380	14-5	IgE has distinctive properties that contrast with those of IgG	406
13-13	Complement defects impair antibody-mediated immunity and cause immune-complex disease	381	14-6	IgE and FcεRI supply each mast cell with a diversity of antigen-specific receptors	407
13-14	Defects in phagocytes result in enhanced susceptibility to bacterial infection	382	14-7	FcεRII is a low-affinity receptor for IgE Fc regions that regulates the production of IgE by B cells	407
13-15	Defects in T-cell function result in severe combined immune deficiencies	383	14-8	Treatment of allergic disease with an IgE-specific monoclonal antibody	409
13-16	Some inherited immunodeficiencies lead to specific disease susceptibilities	385	14-9	Mast cells defend and maintain the tissues in which they reside	410
	Summary	386	14-10	Tissue mast cells orchestrate IgE-mediated reactions through the release of inflammatory mediators	411
	Acquired immune deficiency syndrome	386	14-11	Eosinophils are specialized granulocytes that release toxic mediators in IgE-mediated responses	413
13-17	HIV is a retrovirus that causes a slowly progressing chronic disease	388	14-12	Basophils are rare granulocytes that initiate T <sub>H</sub> 2 responses and the production of IgE	415
13-18	HIV infects CD4 T cells, macrophages, and dendritic cells	388		Summary	415
13-19	In the twentieth century, most HIV-infected people progressed in time to get AIDS	389		IgE-mediated allergic disease	416
13-20	Genetic deficiency of the CCR5 co-receptor for HIV confers resistance to infection	391	14-13	Allergens are protein antigens, some of which resemble parasite antigens	416
13-21	HLA and KIR polymorphisms influence the progression to AIDS	392	14-14	Predisposition to allergic disease is influenced by genetic and environmental factors	418
13-22	HIV escapes the immune response and develops resistance to antiviral drugs by rapid mutation	393	14-15	IgE-mediated allergic reactions consist of an immediate response followed by a late-phase response	419
13-23	Clinical latency is a period of active infection and renewal of CD4 T cells	394	14-16	The effects of IgE-mediated allergic reactions vary with the site of mast-cell activation	420
13-24	HIV infection leads to immunodeficiency and death from opportunistic infections	395	14-17	Systemic anaphylaxis is caused by allergens in the blood	421
13-25	A minority of HIV-infected individuals make antibodies that neutralize many strains of HIV	396	14-18	Rhinitis and asthma are caused by inhaled allergens	423
	Summary	397	14-19	Urticaria, angioedema, and eczema are allergic reactions in the skin	424
	Summary to Chapter 13	398	14-20	Food allergies cause systemic effects as well as gut reactions	426
	Questions	398	14-21	Allergic reactions are prevented and treated by three complementary approaches	427
				Summary	428
				Summary to Chapter 14	428
				Questions	429
				Chapter 15	
				<b>Transplantation of Tissues and Organs</b>	<b>433</b>
				Allogeneic transplantation can trigger hypersensitivity reactions	433
Chapter 14					
<b>IgE-Mediated Immunity and Allergy</b>	<b>401</b>				
14-1	Different effector mechanisms cause four distinctive types of hypersensitivity reaction	401			
	Shared mechanisms of immunity and allergy	403			
14-2	IgE-mediated immune responses defend the body against multicellular parasites	404			
14-3	IgE antibodies emerge at early and late times in the primary immune response	404			
14-4	Allergy is prevalent in countries where parasite infections have been eliminated	406			



15-1	Blood is the most common transplanted tissue	434	Hematopoietic cell transplantation	458	
15-2	Before blood transfusion, donors and recipients are matched for ABO and the Rhesus D antigens	434	15-20	Hematopoietic cell transplantation is a treatment for genetic diseases of blood cells	459
15-3	Incompatibility of blood group antigens causes type II hypersensitivity reactions	435	15-21	Allogeneic hematopoietic cell transplantation is the preferred treatment for many cancers	461
15-4	Hyperacute rejection of transplanted organs is a type II hypersensitivity reaction	436	15-22	After hematopoietic cell transplantation, the patient is attacked by alloreactive T cells in the graft	461
15-5	Anti-HLA antibodies can arise from pregnancy, blood transfusion, or previous transplants	437	15-23	HLA matching of donor and recipient is most important for hematopoietic cell transplantation	462
15-6	Transplant rejection and graft-versus-host disease are type IV hypersensitivity reactions	438	15-24	Minor histocompatibility antigens trigger alloreactive T cells in recipients of HLA-identical transplants	464
	Summary	439	15-25	Some GVHD helps engraftment and prevents relapse of malignant disease	465
	Transplantation of solid organs	440	15-26	NK cells also mediate graft-versus-leukemia effects	466
15-7	Organ transplantation involves procedures that inflame the donated organ and the transplant recipient	440	15-27	Hematopoietic cell transplantation can induce tolerance of a solid organ transplant	467
15-8	Acute rejection is a type IV hypersensitivity caused by effector T cells responding to HLA differences between donor and recipient	441		Summary	467
15-9	HLA differences between transplant donor and recipient activate numerous alloreactive T cells	442		Summary to Chapter 15	468
15-10	Chronic rejection of organ transplants is caused by a type III hypersensitivity reaction	443		Questions	469
15-11	Matching donor and recipient HLA class I and II allotypes improves the success of transplantation	445		Chapter 16	
15-12	Immunosuppressive drugs make allogeneic transplantation possible as routine therapy	445		<b>Disruption of Healthy Tissue by the Adaptive Immune Response</b>	<b>473</b>
15-13	Some treatments induce immunosuppression before transplantation	447	16-1	Every autoimmune disease resembles a type II, III, or IV hypersensitivity reaction	474
15-14	T-cell activation can be targeted by immunosuppressive drugs	448	16-2	Autoimmune diseases arise when tolerance to self antigens is lost	477
15-15	Alloreactive T-cell co-stimulation can be blocked with a soluble form of CTLA4	451	16-3	HLA is the dominant genetic factor affecting susceptibility to autoimmune disease	478
15-16	Blocking cytokine signaling can prevent alloreactive T-cell activation	452	16-4	HLA associations reflect the importance of T-cell tolerance in preventing autoimmunity	480
15-17	Cytotoxic drugs target the replication and proliferation of alloantigen-activated T cells	453	16-5	Binding of antibodies to cell-surface receptors causes several autoimmune diseases	481
15-18	Patients needing a transplant outnumber the available organs	455	16-6	Organized lymphoid tissue sometimes forms at sites inflamed by autoimmune disease	484
15-19	The need for HLA matching and immunosuppressive therapy varies with the organ transplanted	456	16-7	The antibody response to an autoantigen can broaden and strengthen by epitope spreading	485
	Summary	457	16-8	Intermolecular epitope spreading occurs in systemic autoimmune disease	487
			16-9	Intravenous immunoglobulin is a therapy for autoimmune diseases	489

16-10	Monoclonal antibodies that target TNF- $\alpha$ and B cells are used to treat rheumatoid arthritis	490	17-10	Vaccination against human papillomaviruses can prevent cervical and other genital cancers	519
16-11	Rheumatoid arthritis is influenced by genetic and environmental factors	491	17-11	Vaccination with tumor antigens can cause cancer to regress but it is unpredictable	520
16-12	Autoimmune disease can be an adverse side-effect of an immune response to infection	492	17-12	Monoclonal antibodies that interfere with negative regulators of the immune response can be used to treat cancer	521
16-13	Noninfectious environmental factors affect the development of autoimmune disease	494	17-13	T-cell responses to tumor cells can be improved with chimeric antigen receptors	522
16-14	Type 1 diabetes is caused by the selective destruction of insulin-producing cells in the pancreas	495	17-14	The antitumor response of $\gamma\delta$ T cells and NK cells can be augmented	524
16-15	Combinations of HLA class II allotypes confer susceptibility and resistance to type 1 diabetes	496	17-15	T-cell responses to tumors can be improved by adoptive transfer of antigen-activated dendritic cells	525
16-16	Celiac disease is a hypersensitivity to food that has much in common with autoimmune disease	498	17-16	Monoclonal antibodies are valuable tools for the diagnosis of cancer	526
16-17	Celiac disease is caused by the selective destruction of intestinal epithelial cells	498	17-17	Monoclonal antibodies against cell-surface antigens are increasingly used in cancer therapy	528
16-18	Senescence of the thymus and the T-cell population contributes to autoimmunity	501	Summary to Chapter 17		529
16-19	Autoinflammatory diseases of innate immunity	502	Questions		530
	Summary to Chapter 16	503			
	Questions	506			

## Chapter 17

### **Cancer and Its Interactions With the Immune System** 509

17-1	Cancer results from mutations that cause uncontrolled cell growth	510
17-2	A cancer arises from a single cell that has accumulated multiple mutations	510
17-3	Exposure to chemicals, radiation, and viruses facilitates progression to cancer	512
17-4	Certain common features distinguish cancer cells from normal cells	513
17-5	Immune responses to cancer have similarities with those to virus-infected cells	514
17-6	Allogeneic differences in MHC class I molecules enable cytotoxic T cells to eliminate tumor cells	515
17-7	Mutations acquired by somatic cells during oncogenesis can give rise to tumor-specific antigens	516
17-8	Cancer/testis antigens are a prominent type of tumor-associated antigen	517
17-9	Successful tumors evade and manipulate the immune response	518